Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab

Tiziana Life Sciences, Ltd. announced that the second patient with non-active SPMS receiving intranasal foralumab had shown additional clinical improvements since their last reported improvement in September 2022.